2^nd Annual Virtual Biopharma Comms Forum: Day 2

Biopharma corporate affairs now carries weight across policy, investor relations, digital, AI, and culture, often without a title that says so. We’re advising the C-suite and the board on decisions we don’t always own, connecting dots across functions while shouldering responsibility for how those decisions land. Yet the expectations around this expanded remit often come with unclear decision rights and no shared definition of where communications advises and where it decides. During this panel, we’ll discuss what corporate affairs owns today, where the boundaries sit, and what it means to be accountable for clarity even on calls the function doesn’t control.

Why Attend

• Pinpoint when corporate affairs should advise, decide, or own the outcome outright, and what that shift looks like with the C-suite and board.
• Recognize how leaders build one narrative across legal, investor relations, government affairs, and digital when no single function owns the full picture.
• Weigh what an expanding remit means for how you organize a team, set priorities and hiring, when the scope keeps growing.
• Consider how the choice between a centralized corporate affairs model and a narrower scope shapes credibility and speed across the industry.

Every communicator gives advice that shapes a decision somewhere up the chain, but few of us ever hear what happened once we left the room. This fireside chat flips the usual format, putting a communicator in the interviewer’s seat to ask a biotech CEO or CFO what it’s like to sit on the receiving end of that direction. The executive will reflect on moments when that counsel shaped a decision, moments when it missed the mark, and what owning the outcome looks like from the executive’s chair.